Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo - Wikidata - wikimedia - TriplyDB

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

http://www.wikidata.org/entity/Q24603976

about

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid ApoE promotes the proteolytic degradation of Abeta The amyloid hypothesis of Alzheimer's disease at 25 years Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer's disease Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics TREM2 in CNS homeostasis and neurodegenerative disease Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1 Clearance systems in the brain-implications for Alzheimer disease Clinical trial methodologies for disease-modifying therapeutic approaches The Glymphatic System: A Beginner's Guide Alzheimer's disease: Unique markers for diagnosis & new treatment modalities Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion Molecular profiling reveals diversity of stress signal transduction cascades in highly penetrant Alzheimer's disease human skin fibroblasts Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics In vivo human apolipoprotein E isoform fractional turnover rates in the CNS The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide Decreased clearance of CNS beta-amyloid in Alzheimer's disease Sleep drives metabolite clearance from the adult brain Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein.Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers The concentration of soluble extracellular amyloid-β protein in acute brain slices from CRND8 mice.Imaging the Perivascular Space as a Potential Biomarker of Neurovascular and Neurodegenerative Diseases.Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scans Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo Multimodal techniques for diagnosis and prognosis of Alzheimer's disease CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics.Cerebrospinal fluid biomarkers of Alzheimer's disease.Targeting Abeta and tau in Alzheimer's disease, an early interim report Continuous 24-hour leptin, proopiomelanocortin, and amino acid measurements in human cerebrospinal fluid: correlations with plasma leptin, soluble leptin receptor, and amino acid levels Multifaceted Roles of Metzincins in CNS Physiology and Pathology: From Synaptic Plasticity and Cognition to Neurodegenerative Disorders A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease Enhancing astrocytic lysosome biogenesis facilitates Aβ clearance and attenuates amyloid plaque pathogenesis Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.Picomolar amyloid-β peptides enhance spontaneous astrocyte calcium transients Future prospects for biomarkers of alcohol consumption and alcohol-induced disorders Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound

P2860

Q24604376-AB197D67-F162-4E8D-A2E4-A49CD5DA90D5 Q24649556-262F52E1-E4F9-4BFF-ACC7-197B3F42463F Q24651102-DEEA1107-4B3C-4C04-B6E1-85CD5121C2AA Q26749528-54B6B51C-EF10-4944-97F9-638FD18E985F Q26753192-DB91E1EF-1DD4-437B-A2C3-BC5A71FD7100 Q26770708-6B5E8429-2961-475C-B4CB-D2220519A2EE Q26784569-57B1AE6F-1B9B-4A9E-8CCA-C1B32F9D437F Q26785919-F1C5399C-395C-49BE-850E-6F166A55B49D Q26800063-49666980-9B8D-4FA4-B15E-448CE2332BF3 Q26801541-47A893BE-1B70-460D-92C1-D6F25051C978 Q27001770-619FB396-6249-489D-9A1E-4B008424036C Q28084591-B3E798E0-5D93-4955-A98C-1D534BAAF623 Q28085139-5612E553-464C-43F5-ADEA-A5595306197A Q28294279-628DB1EB-50C8-4A2A-9B03-D0926D8CB533 Q28474877-16E7415F-4FF2-4AF9-9D25-35BDB7838C6C Q28681651-82F78A58-66D6-451D-A1D9-387B39714D3A Q28728902-37555AE2-BFF1-4087-8F73-CB5F7236C7FF Q28854601-6B5E8B85-55E2-4C74-A5A8-805DD2A28496 Q29616534-868FE8BA-7A4C-48EF-ABA7-BDD038B1D087 Q29620065-209F36C8-6967-4583-A6A1-BD95FB7BFB7F Q30481489-C37837A9-56F3-42A4-A8DA-C7C67E025264 Q30557695-CBEAA7D9-1E8D-4C82-919C-E9774BCF32BA Q30994762-CF023D36-F282-4A5D-AB33-97D53A745503 Q31060747-E6A1F046-9E25-4744-B9F9-B9A5779FC616 Q33367347-CA803A57-0844-4327-9D93-5225037C362C Q33496258-A6039C71-6A70-482C-9238-75B36DE6E952 Q33592247-EBF0E449-0455-4EDC-BBA7-34A56F505D50 Q33607535-EC4543A4-7221-4C0D-8B38-6F0E5FD7884A Q33735544-FBE370B0-8BD9-4089-8CFC-24E4F7A2E8DF Q33744873-BA04BB50-6E7C-4D9B-A455-BFABF1C10F32 Q33757828-1AF0E5D3-219F-4658-AE88-6078348A5C9A Q33829008-8CDE7D8B-64A2-4726-9328-B0A81D0CC4E0 Q33837121-4A905675-4FBF-4A86-8E9F-A8A7EBF39124 Q33854483-DE8C15E8-C1DB-4B5E-B2CE-0C3B3E193D89 Q33877903-E138143E-DA5D-4C47-8BEC-9EAF64238667 Q33906596-436C1A22-191E-492A-9918-F499553C0929 Q33908201-1DE3C38A-43BB-43ED-9828-7D0DDE1821A7 Q33975923-EAB9052A-A960-4A5C-A5F3-4C57066E24AF Q33976216-B9BF23EB-39B8-4B73-9DF2-6DAA570D07B2 Q34036136-54B21853-0D38-4F5C-9686-A953FFD7AB79

P2860

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

http://www.wikidata.org/entity/Q24603976

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@ast

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@en

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@nl

type

label

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@ast

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@en

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@nl

prefLabel

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@ast

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@en

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@nl

P1433

Q24603976-A931498A-B352-4D83-8CF1-348521F61F6E

P1476

Q24603976-277121C8-99DF-497C-BA14-F95B67B8D135

P2093

Q24603976-4DCBB8F7-4466-49FF-9EE5-2D20AA6AD972

Q24603976-ABEB5DDC-D5BD-4D54-A468-9440ACB15D24

P2860

Q24603976-193496C8-AB49-4814-9C01-D74F1E481122

Q24603976-20E4C815-CC7A-405A-98A1-5C544CC64CC1

Q24603976-2FB04100-A173-40C6-93F1-4E19C621DEDF

Q24603976-33331B41-9041-425E-A7DD-0A031AEEBD34

Q24603976-3A7FA57E-1CBE-4508-AB6F-986294933A57

Q24603976-43D52D92-E17F-4DEC-B600-C35F178BA36F

Q24603976-4767146F-2932-451E-9686-955C4F5B705A

Q24603976-4B665971-CFD9-4BBF-B248-3CCEA6FD46D1

Q24603976-5B7ACBB3-CA81-4E3A-86B6-8A8732ED5647

Q24603976-60D761D8-4BC8-48CE-9FDE-3F7D5034BCEB

P2888

Q24603976-9C90CB05-8626-4670-8549-5DDBBF9FC330

P304

Q24603976-A91F1B6C-1E96-4EF6-A88F-258CCB540663

P31

Q24603976-83FB6035-CA8C-4240-9539-786011689FF4

P3181

Q24603976-8B1B4137-FB31-43A0-8DB6-4A33A442E569

P356

Q24603976-5643C857-7C53-42E1-894B-D371C384683E

P407

Q24603976-D844DC7D-9DB3-4463-BBF8-320AB9D34B53

P433

Q24603976-ECD3E53F-7211-4707-9853-87DA056D07A1

P478

Q24603976-F46EC829-A2E1-488E-AB5D-0376A5C04D75

P50

Q24603976-0E72DE7D-C0F3-4FB9-876B-CB2102A640A5

Q24603976-292CF430-C975-4FC6-92D6-F811D7B26FD9

Q24603976-41DBCD95-268F-4741-92F6-EBAFCD30D375

Q24603976-F25A5A23-D023-4DD3-A022-89E65C710B9F

P577

Q24603976-5E6F43F0-862E-45B5-A0AD-8464A9A80385

P5875

Q24603976-C3B63087-57C6-45CD-9255-42A5617D1C01

P6179

Q24603976-ECA97943-148C-482A-BDFE-7C8C605D4019

P698

Q24603976-162E15D4-2AA7-4CDB-9F9E-C4B901C82D87

P921

Q24603976-823E6E11-5275-4631-8867-F02DB6CB38A5

P932

Q24603976-933EC9C6-3922-4D9F-9530-9D30A4A9F961

P3181

P356

P1433

Nature Medicine

P1476

Human amyloid-beta synthesis a ...... in cerebrospinal fluid in vivo

@en

P2093

Ling Y Munsell

http://www.w3.org/2001/XMLSchema#string

Robert Swarm

http://www.w3.org/2001/XMLSchema#string

P2860

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

Alzheimer's disease: genes, proteins, and therapy

Exercise, aging, and muscle protein metabolism

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.

Isolation of human skeletal muscle myosin heavy chain and actin for measurement of fractional synthesis rates

Reducing plasma HIV RNA improves muscle amino acid metabolism.

Regulation of muscle protein by amino acids.

Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting.

Regulation of skeletal muscle protein metabolism in catabolic states.

P2888

P304

856-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1574352

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NM1438

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Randall J. Bateman

Kevin Yarasheski

David M. Holtzman

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6984116

http://www.w3.org/2001/XMLSchema#string

P6179

1027986631

http://www.w3.org/2001/XMLSchema#string

P698

16799555

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

2983090

http://www.w3.org/2001/XMLSchema#string